<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        4-683-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SEVOFLURANE Inhalation Anesthetic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SEVOFLURANE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Inhalation use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Inhalation vapour, liquid
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        477.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BAXTER HEALTHCARE CORPORATION" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BAXTER HEALTHCARE CORPORATION
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 416]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Arabian Health Care Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BAXTER HEALTHCARE CORPORATION
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N01AB08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Sevoflurane contains sevoflurane. Sevoflurane is a general anaesthetic used in surgery in adults and children. It is an inhalation anaesthetic (it is given to you as a vapour for you to breathe in). Breathing in sevoflurane vapour causes you to fall into a deep, painless sleep. It also maintains a deep, painless sleep (general anaesthesia) during which you can undergo surgery.</p><p>&nbsp;</p><p>You must talk to a doctor if you do not feel better or if you feel worse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Sevoflurane should be administered only by healthcare professionals appropriately trained in the administration of general anaesthesia under the supervision of or by an anaesthetist.</p><p>&nbsp;</p><p><strong>Your anaesthetist (doctor) will not give you Sevoflurane if:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic (hypersensitive) to sevoflurane or other inhalation anaesthetics.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a history of confirmed inflamed liver (hepatitis) due to sevoflurane or other inhalation anaesthetics or you have a history of unexplained liver problems with jaundice, fever, and an increased number of a certain type of white blood cells.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a known or suspected susceptibility to malignant hyperthermia (a sudden and dangerously high increase in body temperature during or shortly after surgery).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; there are medical reasons why you should not be given a general anaesthetic</p><p><br />If any of the above applies, please inform your anaesthetist (doctor) before you are given this medicine.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Sevoflurane if:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have previously been given an inhalation anaesthetic, particularly if this was more than once over a short period of time (repeated use).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have low blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are hypovolemic (reduced blood volume) or weak</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have impaired kidney function</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are pregnant or breastfeeding or when this medicinal product is given for obstetrical anaesthesia (delivery of a baby) (see also section entitled &ldquo;Pregnancy and breastfeeding&rdquo;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a coronary artery disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a risk of increased pressure within the brain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have or previously had liver problems, e.g. hepatitis (inflamed liver) or jaundice</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;you are being treated with a medicine that may cause liver problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are known to have or are at risk of developing convulsions (seizures)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; in the rare and unforeseen instance you develop malignant hyperthermia (a sudden and dangerously high increase in body temperature during or shortly after surgery). In this case your anaesthetist (doctor) will stop the administration of sevoflurane and you will be given a medicine to treat the malignant hyperthermia (known as dantrolene) and you will receive other supportive therapy. Fatal outcome of malignant hyperthermia has been reported with sevoflurane.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a neuromuscular disease e.g. Duchenne muscular dystrophy.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a disorder of the cells (a condition called mitochondrial disorder)</p><p>&nbsp;</p><p>Children</p><p>&nbsp;</p><p>- you have Down syndrome</p><p><strong>&nbsp;</strong></p><p>If any of the above apply to you check with your doctor, nurse or pharmacist. You may need to be checked carefully and your treatment may be changed.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Sevoflurane:</strong></p><p>Please inform your doctor, pharmacist, surgeon or anaesthetist if you are taking, have recently taken or might take any other medicines. This also applies to herbal medicinal products, vitamins and minerals.</p><p>&nbsp;</p><p>The medicines or active substances contained in the medicines listed below may influence each other&rsquo;s effect when used together with Sevoflurane. Some of these medicines are given to you during your surgery by your anaesthetist, as indicated in the description.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nitrous oxide: This is a medicine used during general anaesthesia that will cause you to sleep and will ease your pain.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Opioids (e.g. morphine. fentanyl, remifentanil): These medicines are strong pain killers and are often used during general anaesthesia.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-depolarising muscle relaxants (e.g. pancuronium, atracurium): These medicines are used during general anaesthesia to relax your muscles.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Benzodiazepines (e.g. diazepam, lorazepam): These are sedative medicines, which have a calming effect. They are used when you feel nervous for instance before your surgery.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adrenaline: This medicine is often used to treat allergic reactions, but can also be used during general anaesthesia.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Verapamil: This is a heart medicine, and it is given to treat a high blood pressure or when you suffer from an irregular heart beat.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Beta-blockers (e.g. atenolol, propranolol): These are heart medicines often given to treat a high blood pressure.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Indirect sympathomimetic drugs e.g.: amphetamines (used to treat attention-deficit hyperactivity disorder (ADHD) or narcolepsy) or ephedrine (used as a decongestant and commonly found in cough and cold medicines)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Isoniazid: A medicine used to treat tuberculosis (TB)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alcohol</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St John&rsquo;s Wort: this is a herbal remedy used for depression.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Sevoflurane with food and drink</strong></p><p>Sevoflurane is a medicine to make and keep you asleep so you can undergo surgery. You should ask your doctor, surgeon or anaesthetist when and what you can eat or drink after you wake up.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby ask your doctor, surgeon or anaesthetist for advice before this medicine is given to you.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Sevoflurane severely influences your ability to drive and operate tools. Do not drive or operate tools or machines until your doctor tells you it is safe. Receiving an anaesthetic may influence your alertness for several days. This may affect your ability to carry out tasks that require mental alertness.</p><p>Ask your anaesthetist when it will be safe for you to drive and use machines again.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Sevoflurane will be given to you by an anaesthetist. The anaesthetist will decide on how much you need and when it is to be given. The dose will vary according to your age, weight, the type of surgery you need, and other medicines given to you during surgery.</p><p>&nbsp;</p><p>Sevoflurane is produced from liquid sevoflurane in a vaporiser, specifically designed for use with sevoflurane. &nbsp;You may be asked to breathe the sevoflurane vapour through a mask to make you asleep. You may also be given an injection of another anaesthetic to make you sleep before being given sevoflurane through a mask or a tube in your throat.</p><p>&nbsp;</p><p>Your anaesthetist will decide when to stop giving you Sevoflurane. You will then wake up in a few minutes.</p><p>&nbsp;</p><p><strong>If you receive more Sevoflurane than you should</strong></p><p>Sevoflurane will be given to you by a healthcare professional and it is not likely that you will receive too much Sevoflurane. If you are given too much Sevoflurane, your anaesthetist will take any necessary measures.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Most side effects are mild to moderate in their severity and are brief but there may be some serious side effects.</p><p>&nbsp;</p><p><strong>Serious side effects </strong>(can be life-threatening)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaphylaxis and anaphylactoid reactions (see not known side effects section for more information).</p><p>&nbsp;</p><p>If these symptoms should occur whilst you are being given Sevoflurane, your anaesthetist will take appropriate action.</p><p>&nbsp;</p><p><strong>Very common side effects</strong> <strong>(affects more than 1 user in 10)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; agitation (being restless and disturbed).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slower heart rate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea (feeling sick) and vomiting (being sick)</p><p>&nbsp;</p><p><strong>Common side effects (affects 1 to 10 users in 100)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drowsiness or feeling very sleepy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast heart rate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathing disorder</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; airway obstruction</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slow and shallow breathing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; throat cramping</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased salivation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased or reduced number of white blood cells, which might affect the immune system, i.e. increased susceptibility to infections</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of glucose (sugar) in the blood, as detected by a blood sample test.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increases in liver enzymes, as detected by a blood sample test.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased level of fluoride in the blood, as detected by a blood sample test.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced body temperature</p><p>&nbsp;</p><p><strong>Uncommon side effects</strong><strong> (affects 1 to 10 users in 1,000)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart thumping or irregular heart beat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; AV blockade (a disorder of the electrical conduction of the heart)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; apnoea (when you stop breathing)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; asthma</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypoxia (a low level of oxygen in the blood)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood creatinine levels (an indicator of poor kidney function), as detected by a blood sample test.</p><p>&nbsp;</p><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions e.g.:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness of the skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urticaria (hives)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen eyelids</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathing difficulties</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaphylaxis and anaphylactoid reactions. These allergic reactions occur quickly and can be life-threatening. Symptoms of anaphylaxis include:</p><p>- angioedema (swelling of the skin of the face, limbs, lips, tongue or throat)</p><p>- breathing difficulties</p><p>- low blood pressure</p><p>- urticaria (hives)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confused mental state</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; epilepsy-like fits</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden twitching movements</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cardiac arrest</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cramping of the airways</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in breathing or wheezing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breath holding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced liver function or hepatitis (inflamed liver), characterised by e.g. loss of appetite, fever, nausea, vomiting, abdominal discomfort, jaundice and dark urine.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dangerously raised body temperature</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest discomfort</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a rise in the pressure inside the skull</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irregular heart beat or palpitations</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increases in blood potassium&nbsp; levels as detected by a blood sample test</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle stiffness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellow-looking skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the kidneys (symptoms may include fever, confusion or sleepiness, rash, swelling, more or less urine than normal, and blood in the urine)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling</p><p>&nbsp;</p><p>Sometimes seizures (fits) are seen. These can occur when receiving Sevoflurane, or up to a day later during recovery. They occur mostly in children and young adults.</p><p>&nbsp;</p><p>In children with Down Syndrome who receive sevoflurane, a slowing of the heart rate can occur.</p><p>&nbsp;</p><p>Levels of fluoride in the blood may be raised slightly during and immediately after anaesthesia, but these levels are not thought to be harmful and soon return to normal.</p><p>&nbsp;</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in the leaflet, please tell your doctor or pharmacist.</p><p>&nbsp;</p><p>If you notice any change in the way you feel after receiving sevoflurane, please inform your doctor or pharmacist. Some side effects may need treatment.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, surgeon or anaesthetist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed below. By reporting side effects you can help provide more information on the safety of this medicine.</p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s):</strong></p><p>&nbsp;</p><ul><li><strong>Saudi Arabia:</strong></li></ul><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not store above 30&ordm;C.</p><p>Do not refrigerate or freeze.</p><p>Store in upright position with cap firmly in place.</p><p>Keep this medicine out of sight and reach of children.</p><p>Do not use Sevoflurane after the expiry date that is printed on the label. The expiry date refers to the last day of that month.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is sevoflurane 100% (250 ml in a 250 ml bottle).</p><p>There are no other ingredients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Sevoflurane is a clear, colourless inhalation vapour, liquid.
It is supplied in 250 ml aluminium bottles with a protective lining. 
The bottle may be closed with
-	a plastic screw-on cap; 
or
-	an integrated valve that connects directly to an appropriate vaporisor.

Pack sizes of 1 and 6 bottles.

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer</p><p>&nbsp;</p><p><strong>MARKETING AUTHORISATION HOLDER</strong></p><p>Baxter Healthcare Corporation</p><p>Deerfield</p><p>60015</p><p>IL, USA</p><p>&nbsp;</p><p><strong>MANUFACTURER</strong></p><p>Baxter Healthcare Corporation</p><p>Route 3 Km 144.2</p><p>00784</p><p>Guayama</p><p>Puerto Rico</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in March 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي سيفوفلوران على مادة سيفوفلوران. سيفوفلوران هو مخدر عام يستخدم في العمليات الجراحية التي تُجرى للبالغين والأطفال. وهو مخدر استنشاقي (يعطى في صورة بخار لاستنشاقه). إن استنشاق بخار سيفوفلوران يجعلك تنام نومًا عميقًا دون الشعور بأي ألم. كما أنه يبقيك في حالة نوم عميق دون الشعور بأي ألم (تخدير عام)، يمكن أن تخضع خلالها لعملية جراحية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن تتحدث إلى طبيب إذا لم تشعر بتحسن أو إذا ازدادت حالتك سوءًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا يُعطى سيفوفلوران إلا بالاستعانة بمتخصصي الرعاية الصحية الذين تلقوا تدريبًا كافيًا في قسم التخدير العام تحت إشراف، أو بواسطة، طبيب تخدير.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لن يعطيك طبيب التخدير (الطبيب) سيفوفلوران إذا:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت لديك حساسية (فرط حساسية) من سيفوفلوران أو أي مواد تخدير استنشاقية أخرى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك تاريخ من حدوث إصابة مؤكدة بالتهاب في الكبد (التهاب كبدي) بسبب استخدام سيفوفلوران أو أي مواد تخدير استنشاقية أخرى أو لديك تاريخ من حدوث مشاكل في الكبد غير معروفة السبب مصحوبة باليرقان والحمى وارتفاع في عدد نوع معين من خلايا الدم البيضاء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا أو مشتبه في إصابتك بفرط الحرارة الخبيث (ارتفاع مفاجئ وخطير في درجة حرارة الجسم أثناء الجراحة أو بعد إجرائها بفترة قصيرة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت لديك أسباب طبية تمنعك من استخدام مخدر عام</p><p dir="RTL"><br /><br />إذا انطبقت عليك أي من الحالات السابقة، يرجى إبلاغ طبيب التخدير (الطبيب) قبل إعطائك هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL"><strong>تحدث إلى الطبيب أو الصيدلي قبل استخدام سيفوفلوران إذا:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم إعطاؤك مخدر استنشاقي في السابق، ولاسيما إذا حدث ذلك أكثر من مرة خلال فترة زمنية قريبة (استخدام متكرر).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من انخفاض في ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من نقص حجم الدم (انخفاض حجم الدم) أو من الضعف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من اختلال في وظائف الكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملاً أو ترضعين رضاعة طبيعية أو عند إعطاء هذا المستحضر الطبي للتخدير أثناء الولادة (عند ولادة طفل) (يرجى الرجوع إلى القسم &quot;الحمل والرضاعة الطبيعية&quot;)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مُصابًا بأحد أمراض الشريان التاجي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت معرضًا لارتفاع الضغط داخل المخ</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت لديك مشكلات في الكبد في السابق، مثل الالتهاب الكبدي (التهاب الكبد) أو اليرقان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;خضعت للعلاج بدواء قد يسبب مشكلات في الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني بالفعل من تشنجات متطورة (نوبات) أو هناك احتمالية أن تتعرض للإصابة بها</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; في الحالات النادرة وغير المتوقعة التي تتعرض فيها للإصابة بفرط الحرارة الخبيث (ارتفاع مفاجئ وخطير في درجة حرارة الجسم أثناء الجراحة أو بعد إجرائها بفترة قصيرة). وفي هذه الحالة سيقوم طبيب التخدير (الطبيب) بإيقاف استخدام سيفوفلوران وسيتم إعطاؤك دواءً لعلاج فرط الحرارة الخبيث (المعروف بدانترولين) وستتلقى علاجًا داعمًا آخر. تم الإبلاغ عن نتائج قد تمثل تهديدًا للحياة نتيجة الإصابة بفرط الحرارة الخبيث عند استخدام سيفوفلوران.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك مرض عصبي عضلي مثل الحَثَل العضلي الدُوشيني.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك اضطراب في الخلايا (حالة تسمى اضطراب مُتَقَدِّري)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كانت هناك إصابة بمتلازمة داون</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا انطبقت عليك أي من الحالات السابقة، تحدث إلى الطبيب أو الممرضة أو الصيدلي. قد تكون بحاجة إلى الفحص بعناية وقد يتم تغيير علاجك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى وسيفوفلوران:</strong></p><p dir="RTL">يرجى إبلاغ الطبيب أو الممرضة أو الجراح أو طبيب التخدير إذا كنت تتناول أو تناولت مؤخرًا أو ربما تتناول أي أدوية أخرى. ينطبق ذلك أيضًا على المستحضرات الطبية العشبية والفيتامينات والمعادن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تؤثر الأدوية أو المواد الفعالة التي تحتوي عليها الأدوية الواردة أدناه على فعالية بعضها البعض عند استخدامها مع سيفوفلوران. تُعطى بعض من هذه الأدوية أثناء الجراحة بواسطة طبيب التخدير، على النحو المذكور في الوصف.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أكسيد النيتروز: يستخدم هذا الدواء أثناء التخدير العام الذي يجعلك تنام ويريحك من الألم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد الأفيونية (مثل المورفين والفينتانيل والريميفنتانيل): هذه الأدوية هي مسكنات ألم قوية المفعول وكثيرًا ما تستخدم أثناء التخدير العام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مُرخيات عضلات غير مُزيلة للاستقطاب (مثل بانكورونيوم، أتراكوريوم): تستخدم هذه الأدوية أثناء التخدير العام لإرخاء العضلات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بنزوديازيبينات (مثل الديازيبام، اللورازيبام): هذه الأدوية هي أدوية مُهدئة ولها تأثير مُهدئ. وهي تستخدم عندما تشعر بالتوتر على سبيل المثال قبل الخضوع لعملية جراحية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدرينالين: كثيرًا ما يستخدم هذا الدواء لعلاج تفاعلات الحساسية، ولكن يمكن استخدامها أيضًا أثناء التخدير العام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيراباميل: هذا الدواء هو دواء للقلب، ويعطَى لعلاج ارتفاع ضغط الدم أو عندما تعاني من عدم انتظام نبضات القلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاصرات مستقبلات بيتا (مثل أتينولول وبروبرانولول): هذه الأدوية هي أدوية للقلب وكثيرًا ما تستخدم لعلاج ارتفاع ضغط الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية محاكية الوُدي غير مباشرة، مثل: الأمفيتامينات (تستخدم لعلاج اضطراب نقص الانتباه مع فرط النشاط (ADHD) أو التغفيق) أو إفيدرين (يستخدم كمزيل للاحتقان ومن الشائع وجوده في أدوية الكحة والبرد)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آيزونيازيد: دواء يُستخدم لعلاج مرض السل (TB)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكحول</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جون: هي علاج عشبي يستخدم لعلاج الاكتئاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام سيفوفلوران مع الطعام والشراب</strong></p><p dir="RTL">سيفوفلوران هو دواء يبقيك نائمًا حتى يتسنى إجراء عملية جراحية لك. ويجب أن تسأل الطبيب أو الجراح أو طبيب التخدير متى يمكنك تناول طعام أو شراب بعد إفاقتك وما المسموح بتناوله.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">إذا كنتِ حاملاً أو ترضعين رضاعة طبيعية أو تحتملين وجود حمل أو تخططين للإنجاب، استشيري الطبيب أو الجراح أو طبيب التخدير قبل أن يتم إعطاؤك هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">يؤثر سيفوفلوران بشكل حاد على قدرتك على القيادة وتشغيل الآلات. يجب تجنب القيادة أو تشغيل آلات أو ماكينات إلى أن يخبرك الطبيب أن هذا آمن لك. قد يؤثر تلقي مخدر على انتباهك لعدة أيام. وبالتالي قد يؤثر على قدرتك على القيام بمهام تتطلب الانتباه العقلي.</p><p dir="RTL">اسأل طبيب التخدير متى يمكنك معاودة القيادة واستخدم الآلات بشكل آمن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيقوم طبيب تخدير بإعطائك سيفوفلوران. وسيقرر طبيب التخدير كمية الجرعة التي تحتاجها ومتى يجب إعطاؤها. ستختلف الجرعة حسب عمرك ووزنك ونوع الجراحة التي تحتاجها والأدوية الأخرى التي يتم إعطاؤها لك أثناء الجراحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُصنَّع سيفوفلوران من سائل السيفوفلوران في مبخرة صُممت خصيصًا للاستخدام مع سيفوفلوران.&nbsp; قد يُطلب منك استنشاق بخار سيفوفلوران من خلال كمامة ليجعلك تنام. قد تُعطى حقنة من مخدر آخر كي تنام قبل إعطاؤك سيفوفلوران بواسطة كمامة أو أنبوب يوضع في الحلق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقرر طبيب التخدير متى يتم التوقف عن إعطائك سيفوفلوران. ستفوق من التخدير خلال بضع دقائق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تلقيت جرعة زائدة من سيفوفلوران</p><p dir="RTL">سوف تُعطى سيفوفلوران بواسطة متخصص رعاية صحية ومن غير المحتمل أنك ستتلقى جرعة زائدة من سيفوفلوران. إذا تلقيت جرعة زائدة من سيفوفلوران ، سيتخذ طبيب التخدير أية إجراءات ضرورية.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يتسبب هذا الدواء، كغيره من الأدوية، في حدوث آثار جانبية، ولكن ليس بالضرورة أن تحدث هذه الآثار لجميع الأشخاص.</p><p dir="RTL">تتراوح معظم الآثار الجانبية في شدتها ما بين الخفيفة إلى المتوسطة وتستمر لفترة قصيرة ولكن قد تحدث آثار جانبية خطيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الخطيرة </strong>(قد تهدد الحياة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية وتأقانية (انظر قسم آثار جانبية غير معروفة للحصول على مزيد من المعلومات).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا حدثت هذه الأعراض أثناء إعطائك سيفوفلوران ، سيتخذ طبيب التخدير الإجراء المناسب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة للغاية</strong> <strong>(تؤثر على أكثر من مستخدم واحد من بين كل </strong><strong>10</strong><strong> مستخدمين)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهياج (الشعور بالاضطراب والانزعاج).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبضات قلب أكثر بطئًا</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان (شعور بالإعياء) وقيء (الإصابة بالإعياء)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة (تؤثر على </strong><strong>1</strong><strong> إلى </strong><strong>10</strong><strong> مستخدمين من بين كل </strong><strong>100</strong><strong> مستخدم)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نعاس أو شعور بنعاس شديد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبضات قلب سريعة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع في ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب في التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد مجرى الهواء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تنفس ضحل وبطيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج الحلق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في إفراز اللعاب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رعشة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع أو انخفاض عدد خلايا الدم البيضاء الذي قد يؤثر على جهاز المناعة مما يعني زيادة قابلية الإصابة بالعدوى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى الجلوكوز (السكر) في الدم حسبما يكشف عنه اختبار عينة الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع انزيمات الكبد، حسبما يكشف عنه اختبار عينة الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى الفلوريد في الدم، حسبما يكشف عنه اختبار عينة الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض درجة حرارة الجسم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة</strong> (تؤثر على <strong>1</strong> إلى <strong>10</strong> مستخدمين من بين كل <strong>1000</strong> مستخدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشوش</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسارع القلب أو عدم انتظام نبضات قلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحصار أذيني بطيني (اضطراب نظام التوصيل الكهربائي للقلب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انقطاع التنفس (عندما تتوقف عن التنفس)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ربو</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص التأكسج (انخفاض مستوى الأكسجين في الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات الكرياتينين في الدم (مؤشر على ضعف وظيفة الكلى)، حسبما يكشف عنه اختبار عينة الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة</strong> (لا يمكن تقدير معدل التكرار من البيانات المتوفرة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية، مثل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شرى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الجفون صعوبة في التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية وتأقانية. قد تحدث تفاعلات الحساسية بشكل سريع ويمكن أن تهدد الحياة. أعراض الحساسية تشمل:</p><p dir="RTL">&ndash; وذمة وعائية (تورم جلد الوجه أو الأطراف أو الشفاة أو اللسان أو الحلق)</p><p dir="RTL">&ndash; صعوبة في التنفس</p><p dir="RTL">&ndash; انخفاض في ضغط الدم</p><p dir="RTL">&ndash; شرى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة تشوش ذهني</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات تشبه الصرع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات وخز مفاجئة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توقف القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج في الشعب الهوائية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ndash; صعوبة في التنفس أو أزيز في الصدر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انحباس النفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور في وظيفة الكبد أو التهاب كبدي (التهاب الكبد)، يتميز بحدوث أعراض مثل فقدان الشهية وحمى وغثيان وقيء وعدم الشعور بالراحة في البطن ويرقان وغمقان البول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع خطير في درجة حرارة الجسم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بعدم الراحة في الصدر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع في الضغط داخل الجمجمة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبضات قلب غير منتظمة أو خفقان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع في مستويات البوتاسيوم في الدم، حسبما يكشف عنه اختبار عينة الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبس العضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكلى (الأعراض قد تشمل حمى أو تشوش أو نوم وطفح جلدي وتورم وزيادة أو قلة كمية البول عن المعدل الطبيعي ونزول دم في البول)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم</p><p dir="RTL">&nbsp;</p><p dir="RTL">في بعض الأحيان قد تحدث نوبات. يمكن أن تحدث هذه الأمور عند تلقي سيفوفلوران أو تستمر حتى بعد مرور يوم خلال التعافي. وهي تحدث غالبًا لدى الأطفال والبالغين من الشباب.</p><p dir="RTL">قد يحدث بطء في نبضات القلب لدى الأطفال المصابين بمتلازمة داون الذين يتلقون سيفوفلوران.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد ترتفع مستويات الفلوريد في الدم بشكل طفيف أثناء وبعد التخدير مباشرةً، ولكن لا يُعتقد أن تكون هذه المستويات ضارة وسرعان ما تعود إلى مستوياتها الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة تفاقم أي من الآثار الجانبية أو ملاحظة أي آثار جانبية غير واردة في هذه النشرة، يُرجى إبلاغ الطبيب أو الصيدلي.</p><p dir="RTL">إذا لاحظت أي تغيير في حالتك بعد تلقي سيفوفلوران، يرجى إبلاغ الطبيب أو الصيدلي. قد تحتاج بعض الآثار الجانبية إلى علاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الإبلاغ عن الآثار الجانبية</p><p dir="RTL">في حالة تعرضك لأي آثار جانبية، تحدث إلى الطبيب أو الجراح أو طبيب التخدير. ويشمل هذا أي آثار جانبية محتملة غير واردة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً من خلال نظام الإبلاغ الوطني الوارد أدناه. من خلال الإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير المزيد من المعلومات بشأن سلامة هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>للإبلاغ عن أي آثار جانبية:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المملكة العربية السعودية:</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:576px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية (NPC)</p><p dir="RTL">مركز الاتصال التابع لهيئة الغذاء والدواء السعودية: 19999</p><p dir="RTL">&rlm;‫البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&rlm;‫موقع الويب: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>دول مجلس التعاون الخليجي الأخرى:</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:576px"><tbody><tr><td><p dir="RTL">الرجاء الاتصال ﺑﺎﻟﻤﺆﺳﺴﺎت واﻟﮭﯿﺌﺎت اﻟﻮطﻨﯿﺔ المختصة ﻓﻲ ﻛﻞ دوﻟﺔ.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تجنب التخزين في درجة حرارة تزيد عن 30 درجة مئوية</p><p dir="RTL">تجنب تبريد أو تجميد الدواء.</p><p dir="RTL">يحفظ بعيدًا عن متناول ونظر الأطفال.</p><p dir="RTL">تحفظ العبوة بوضع فائم مع التأكد ان الغطاء محكم الاغلاق.</p><p dir="RTL">تجنب استخدام دواء سيفوفلوران بعد تاريخ انتهاء الصلاحية المطبوع على الملصق. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي سيفوفلوران 100% (250 مل في زجاجة حجمها 250 مل).</p><p dir="RTL">ليس هناك مكونات أخرى في الدواء.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">سيفوفلوران هو عبارة عن بخار وسائل استنشاق شفاف ليس له لون.</p><p dir="RTL" style="text-align:right">يُقدم في زجاجة مصنوعة من الألومنيوم يصل حجمها إلى 250 مل وتحتوي على بطانة واقية.</p><p dir="RTL" style="text-align:right">قد تكون الزجاجة مغلقة</p><p dir="RTL" style="text-align:right">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بغطاء حلزوني بلاستيكي</p><p dir="RTL" style="text-align:right">أو</p><p dir="RTL" style="text-align:right">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بصمام مدمج موصل مباشرةً بمبخر مناسب.تكون الزجاجة مغلقة بغطاء حلزوني بلاستيك.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">عبوات تحتوي على زجاجة واحدة أو 6 زجاجات.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">قد لا تتوفر جميع أحجام العبوات في بعض الأسواق.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p style="text-align:right">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق</strong></p><p dir="RTL">Baxter Healthcare Corporation</p><p dir="RTL">Deerfield</p><p dir="RTL">60015</p><p dir="RTL">IL, USA</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">Baxter Healthcare Corporation</p><p dir="RTL">Route 3 Km 144.2</p><p dir="RTL">00784</p><p dir="RTL">Guayama</p><p dir="RTL">Puerto Rico</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة في مارس 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SEVOFLURANE Liquid for Inhalation
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sevoflurane 100% (V/V)  

Excipient with known effect: None

The medicinal product is comprised only of the active substance, see section 6.1.




            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Inhalation vapour, liquid
Clear, colourless liquid


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Induction and maintenance of general anaesthesia in adults and children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Premedication should be selected according to the need of the individual patient, and at the discretion of the anaesthesiologist.</p><p>&nbsp;</p><p><u>Surgical anaesthesia</u></p><p><strong><u>&nbsp;</u></strong></p><p>The concentration of sevoflurane being delivered from a vaporizer during anaesthesia should be known. This may be accomplished by using a vaporizer calibrated specifically for Sevoflurane.&nbsp;</p><p>&nbsp;</p><p><em>Anaesthesia induction</em></p><p>Dosage should be individualised and titrated to the desired effect according to the patient&rsquo;s age and clinical status.</p><p>&nbsp;</p><p>A short acting barbiturate or other intravenous induction agent may be administered followed by inhalation of sevoflurane.</p><p>&nbsp;</p><p>Induction with sevoflurane may be achieved by inhalation of 0.5-1.0% sevoflurane in oxygen (O<sub>2</sub>) with or without nitrous oxide (N<sub>2</sub>O), increasing by increments of 0.5-1.0% sevoflurane, to a maximum of 8% in adults and children until the required depth of anaesthesia is achieved. In adults inspired concentrations of up to 5% sevoflurane usually produce surgical anaesthesia in less than two&nbsp;minutes.&nbsp; In children, inspired concentrations of up to 7% sevoflurane usually produce surgical anaesthesia in less than two&nbsp;minutes.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Maintenance of anaesthesia</em></p><p>Surgical levels of anaesthesia may be maintained by inhalation of 0.5-3% sevoflurane in O<sub>2</sub> with or without concomitant use of N<sub>2</sub>O.</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 1</strong></p><p><strong>MAC Values for Adults and Pediatric Patients According to Age</strong></p></td></tr></tbody><thead><tr><td style="vertical-align:top"><p><strong>Age of Patient</strong></p><p><strong>(Years)</strong></p></td><td style="vertical-align:top"><p><strong>Sevoflurane</strong></p><p><strong>in Oxygen</strong></p></td><td style="vertical-align:top"><p><strong>Sevoflurane</strong></p><p><strong>in 65% N<sub>2</sub>0/35%0<sub>2</sub></strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>0 - 1 months *</p></td><td style="vertical-align:top"><p>3.3%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>1 - &lt; 6 months</p></td><td style="vertical-align:top"><p>3.0%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>6 months - &lt; 3 years</p></td><td style="vertical-align:top"><p>2.8%</p></td><td style="vertical-align:top"><p>2.0%@</p></td></tr><tr><td style="vertical-align:top"><p>3 - 12</p></td><td style="vertical-align:top"><p>2.5%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>2.6%</p></td><td style="vertical-align:top"><p>1.4%</p></td></tr><tr><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>2.1%</p></td><td style="vertical-align:top"><p>1.1%</p></td></tr><tr><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>1.7%</p></td><td style="vertical-align:top"><p>0.9%</p></td></tr><tr><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>1.4%</p></td><td style="vertical-align:top"><p>0.7%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; *&nbsp;&nbsp; Neonates are full-term gestational age. MAC in premature infants has not been determined.</p><p>&nbsp;&nbsp;&nbsp;&nbsp; @ In 1 - &lt;3 year old pediatric patients, 60% N<sub>2</sub>0/40% 0<sub>2</sub> was used.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Emergence</em></p><p>Emergence times are generally short following sevoflurane anesthesia. Therefore, patients may require post-operative pain relief earlier.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>MAC decreases with increasing age. The average concentration of sevoflurane to achieve MAC in an 80 year old is approximately 50% of that required in a 20 year old.&nbsp;</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Refer to Table 1 for MAC values for paediatric patients according to age when used in oxygen with or without concomitant use of nitrous oxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sevoflurane should not be used in patients with known or suspected hypersensitivity to sevoflurane or to other halogenated anaesthetics (e. g. history of liver function disorder, fever or leucocytosis of unknown cause after anesthesia with one of these agents).

Sevoflurane should not be used in patients with a history of confirmed hepatitis due to a halogenated inhalational anesthetic or a history of unexplained moderate to severe hepatic dysfunction with jaundice, fever and eosinophilia after anaesthesia with sevoflurane.

Sevoflurane should not be used in patients with known or suspected  genetic susceptibility to malignant hyperthermia.

Sevoflurane is contraindicated in patients in whom general anesthesia is contraindicated.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sevoflurane should be administered only by persons trained in the administration of general anaesthesia. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment and circulatory resuscitation must be immediately available. All patients anaesthetised with sevoflurane should be constantly monitored, including electrocardiogram (ECG), blood pressure (BP), oxygen saturation and end tidal carbon dioxide (CO<sub>2</sub>).</p><p>&nbsp;</p><p>The concentration of sevoflurane being delivered from a vaporizer must be known exactly. As volatile anaesthetics differ in their physical properties, only vaporizers specifically calibrated for sevoflurane must be used.&nbsp; The administration of general anaesthesia must be individualized based on the patient&#39;s response. Hypotension and respiratory depression increase as anaesthesia is deepened.</p><p>&nbsp;</p><p>During maintenance of anaesthesia, increasing the sevoflurane concentration results in dose-dependent decreases in blood pressure. An excessive reduction in blood pressure may be related to depth of anesthesia and in such instances may be corrected by decreasing the inspired sevoflurane concentration. Due to sevoflurane&rsquo;s insolubility in blood, hemodynamic changes may occur more rapidly than with some other volatile anaesthetics.<strong> </strong>&nbsp;Recovery from general anaesthesia should be assessed carefully before patients are discharged from the post-anaesthesia care unit.</p><p>&nbsp;</p><p>Emergence is generally rapid following sevoflurane anaesthesia; therefore, patients may require early postoperative pain relief.</p><p>&nbsp;</p><p>Although recovery of consciousness following sevoflurane administration generally occurs within minutes, the impact on intellectual function for two or three days following anaesthesia has not been studied. As with other anaesthetics, small changes in moods may persist for several days following administration (see section 4.7).</p><p>&nbsp;</p><p><u>Patients with coronary disease</u></p><p>As with all anaesthetics, maintenance of haemodynamic stability is important in order to avoid myocardial ischaemia in patients with coronary artery disease.</p><p>&nbsp;</p><p><u>Patients undergoing obstetrical procedures</u></p><p>Caution should be exercised in obstetric anaesthesia due to the relaxant effect of sevoflurane on the uterus and increase in uterine haemorrhage (see Section&nbsp;4.6).</p><p>&nbsp;</p><p><u>Patients undergoing neurosurgical procedures</u></p><p>In patients at risk for elevations of ICP, sevoflurane should be administered cautiously in conjunction with ICP-reducing maneuvers such as hyperventilation.</p><p>&nbsp;</p><p><u>Seizures</u></p><p>Rare cases of seizures have been reported in association with sevoflurane use.</p><p>&nbsp;</p><p>Use of sevoflurane has been associated with seizures occurring in children and young adults as well as older adults with and without predisposing risk factors. Clinical judgment is necessary before sevoflurane is used in patients at risk of seizures. In children the depth of anaesthesia should be limited. EEG may permit the optimization of sevoflurane dose and help avoid the development of seizure activity in patients with a predisposition for seizures (see section 4.4 &ndash; Paediatric population).</p><p>&nbsp;</p><p><u>Patients with renal injury</u></p><p>Although data from controlled clinical studies at low flow rates are limited, findings taken from patient and animal studies suggest there is a potential for renal injury, which is presumed due to Compound A. Animal and human studies demonstrate that sevoflurane administered for more than 2 MAC hours and at fresh gas flow rates of &lt;2 L/min may be associated with proteinuria and glycosuria. Also see Section 5.1.</p><p>&nbsp;</p><p>The level of Compound A exposure at which clinical nephrotoxicity might be expected to occur has not been established. Consider all of the factors leading to Compound A exposure in humans, especially duration of exposure, fresh gas flow rate, and concentration of sevoflurane.</p><p>&nbsp;</p><p>Inspired sevoflurane concentration and fresh gas flow rate should be adjusted to minimize exposure to Compound A. Sevoflurane exposure should not exceed 2 MAC hours at flow rates of 1 to &lt;2 L/min. Fresh gas flow rates &lt;1 L/min are not recommended.</p><p>&nbsp;</p><p><u>Patients with renal impairment</u></p><p>Sevoflurane should be administered with caution to patients with impaired renal function (GFR &le; 60 ml/min); renal function should be monitored postoperatively.</p><p>&nbsp;</p><p><u>Patients with liver disease</u></p><p>Very rare cases of mild, moderate or serious post-operative liver dysfunction or hepatitis (with or without jaundice) have been reported from post marketing experience. Clinical judgement should be exercised when sevoflurane is used in patients with underlying liver problems or those who are receiving treatment with medications known to cause liver dysfunction.&nbsp; In patients who have experienced hepatic injury, jaundice, unexplained fever or eosinophilia after administration of other inhalation anaesthetics, it is recommended to avoid administration of sevoflurane if anaesthesia with intravenous medicinal products or regional anaesthesia is possible (see Section&nbsp;4.8).</p><p>&nbsp;</p><p><u>Patients with mitochondrial disorders</u></p><p>Caution should be exercised in administering general anesthesia, including sevoflurane, to patients with mitochondrial disorders.</p><p>&nbsp;</p><p><u>Patient circumstances that warrant consideration</u></p><p>Particular care must be taken when selecting the dosage for hypovolaemic, hypotensive, weakened patients or otherwise hemodynamically compromised, e.g., due to concomitant medications.</p><p>&nbsp;</p><p>Patients with repeated exposures to halogenated hydrocarbons, including sevoflurane, within a relatively short interval may have an increased risk of hepatic injury.</p><p>&nbsp;</p><p>Isolated reports of QT prolongation, very rarely associated with torsade de pointes (in exceptional cases, fatal), have been received. Caution should be exercised when administering sevoflurane to susceptible patients.</p><p>&nbsp;</p><p><u>Malignant hyperthermia</u><u>:&nbsp; </u></p><p>In susceptible individuals, potent inhalation anaesthetic agents may trigger a skeletal muscle hypermetabolic state leading to high oxygen demand and the clinical syndrome known as malignant hyperthermia. Rare cases of malignant hyperthermia have been reported with the use of sevoflurane (see also section 4.8). The clinical syndrome is signalled by hypercapnia, and may include muscle rigidity, tachycardia, tachypnea, cyanosis, arrhythmias, and/or unstable blood pressure. Some of these nonspecific signs may also appear during light anesthesia, acute hypoxia, hypercapnia and hypovolemia.&nbsp; Fatal outcome of malignant hyperthermia has been reported with sevoflurane. Treatment includes discontinuation of triggering agents (e.g. sevoflurane), administration of intravenous dantrolene sodium, and application of supportive therapy. Renal failure may appear later, and urine production should be monitored and sustained if possible. Use of inhaled anesthetic agents has been associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in pediatric patients during the postoperative period.&nbsp;</p><p>&nbsp;</p><p>Patients with latent as well as overt neuromuscular disease, particularly Duchenne muscular dystrophy, appear to be most vulnerable.&nbsp; Concomitant use of succinylcholine has been associated with most, but not all, of these cases.&nbsp; These patients also experienced significant elevations in serum creatine kinase levels and, in some cases, changes in urine consistent with myoglobinuria.&nbsp; Despite the similarity in presentation to malignant hyperthermia, none of these patients exhibited signs or symptoms of muscle rigidity or hypermetabolic state.&nbsp;</p><p>&nbsp;</p><p>Early and aggressive intervention to treat the hyperkalemia and resistant arrhythmias is recommended, as is subsequent evaluation for latent neuromuscular disease.<em> </em></p><p>&nbsp;</p><p><u>Replacement of dried-out CO<sub>2 </sub></u><u>absorbens</u></p><p>The exothermic reaction between sevoflurane and CO<sub>2</sub> absorbent lime is reinforced when the CO<sub>2</sub> absorbent lime is dried out, e.g. after a longer period with current of dry gas over the bottle with CO<sub>2</sub> absorbent lime. Rare cases have been reported of extreme heat, smoke and/or spontaneous fire from the anaesthesia vaporiser during use of sevoflurane together with dried-out absorbent lime, specifically those containing potassium hydroxide.. An unexpected delay in increase of inspired concentration of sevoflurane or an unexpected decrease of inspired concentration of sevoflurane compared with the setting of the vaporiser may be a sign of overheating of the CO<sub>2</sub> absorbent lime bottle.</p><p>&nbsp;</p><p>An exothermic reaction, enhanced sevoflurane degradation, and production of degradation products () can occur when the CO<sub>2</sub> absorbent becomes desiccated, such as after an extended period of dry gas flow through the CO<sub>2</sub> absorbent canisters.&nbsp; Sevoflurane degradants (methanol, formaldehyde, carbon monoxide, and Compounds A, B, C, and D) were observed in the respiratory circuit of an experimental anesthesia machine using desiccated CO<sub>2</sub> absorbents and maximum sevoflurane concentrations (8%) for extended periods of time (&sup3; 2 hours). Concentrations of formaldehyde observed at the anesthesia respiratory circuit (using sodium hydroxide containing absorbents) were consistent with levels known to cause mild respiratory irritation.&nbsp; The clinical relevance of the degradants observed under this extreme experimental model is unknown.</p><p>&nbsp;</p><p>If the treating physician suspects the CO<sub>2</sub> absorbent lime to be dried-out, this must be replaced before the administration of sevoflurane. The colour indicator on most CO<sub>2</sub> absorbent limes does not necessarily change when dried-out. Therefore the absence of marked changed of colour should not be taken as a secure sign of sufficient hydration. CO<sub>2</sub> absorbents must be replaced regularly irrespective of the colour indicator <em>(see Section&nbsp;6.6).</em></p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The use of sevoflurane has been associated with seizures. Many have occurred in children and young adults starting from 2 months of age, most of whom had no predisposing risk factors. Clinical judgment should be exercised when using sevoflurane in patients who may be at risk for seizures (see section 4.4 &ndash; Seizures).</p><p>&nbsp;</p><p>Rapid emergence in children may briefly evoke a state of agitation and hinder cooperation (in about 25% of anaesthetised children).</p><p>&nbsp;</p><p>Isolated cases of ventricular arrhythmia were reported in paediatric patients with Pompe&rsquo;s disease.&nbsp;</p><p>&nbsp;</p><p>Dystonic movements, which disappear without treatment, are seen in children who have received sevoflurane for anaesthesia induction. The relationship to sevoflurane is uncertain.</p><p>&nbsp;</p><p><em>Down syndrome</em></p><p>A significantly higher prevalence and degree of bradycardia has been reported in children with Down syndrome during and following sevoflurane induction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sevoflurane has been shown to be safe and effective when administered concurrently with a wide variety of agents commonly encountered in surgical situations such as central nervous system agents, autonomic drugs, skeletal muscle relaxants, anti-infective agents including aminoglycosides, hormones and synthetic substitutes, blood derivatives and cardiovascular drugs, including epinephrine.</p><p>&nbsp;</p><p><u>Nitrous oxide</u></p><p>As with other halogenated volatile anesthetics, the MAC of sevoflurane is decreased when administered in combination with nitrous oxide. The MAC equivalent is reduced approximately 50% in adult and approximately 25% in pediatric patients (see section 4.2 &ndash; Maintenance). &nbsp;</p><p>&nbsp;</p><p><u>Neuromuscular blocking agents</u></p><p>As with other inhalational anesthetic agents, sevoflurane affects both the intensity and duration of neuromuscular blockade by non-depolarizing muscle relaxants. When used to supplement alfentanil-N<sub>2</sub>O anesthesia, sevoflurane potentiates neuromuscular block induced with pancuronium, vecuronium or atracurium. The dosage adjustments for these muscle relaxants when administered with sevoflurane are similar to those required with isoflurane. The effect of sevoflurane on succinylcholine and the duration of depolarizing neuromuscular blockade has not been studied.</p><p>&nbsp;</p><p>Dosage reduction of neuromuscular blocking agents during induction of anesthesia may result in delayed onset of conditions suitable for endotracheal intubation or inadequate muscle relaxation because potentiation of neuromuscular blocking agents is observed a few minutes after the beginning of sevoflurane administration.&nbsp;</p><p>&nbsp;</p><p>Among non-depolarizing agents, vecuronium, pancuronium and atracurium interactions have been studied. In the absence of specific guidelines: (1) for endotracheal intubation, do not reduce the dose of non-depolarizing muscle relaxants; and, (2) during maintenance of anesthesia, the dose of non-depolarizing muscle relaxants is likely to be reduced compared to that during N<strong><em><sub>2</sub></em></strong>O/opioid anesthesia. Administration of supplemental doses of muscle relaxants should be guided by the response to nerve stimulation<sub>.&nbsp;&nbsp; </sub>&nbsp;</p><p>&nbsp;</p><p><u>Benzodiazepines and opioids</u></p><p>Benzodiazepines and opiates are expected to decrease the MAC of sevoflurane to the same manneras other inhaled anaesthetics. Sevoflurane administration is compatible with benzodiazepines and opioids as commonly used in surgical practice.</p><p>&nbsp;</p><p>Opioids such as fentanyl, alfentanil and sufentail, when combined with sevoflurane, may lead to a synergistic fall in heart rate, blood pressure and respiratory rate.</p><p>&nbsp;</p><p><u>Beta blockers</u></p><p>Sevoflurane may increase the negative ionotropic, chronotropic and dromotropic effects of beta blockers through blockade of cardiovascular compensation mechanisms.</p><p>&nbsp;</p><p><u>Epinephrine/adrenaline</u></p><p>Sevoflurane is similar to isoflurane in the sensitisation of the myocardium to the arrhythmogenic effect of exogenously administered adrenaline, the threshold dose of adrenaline producing multiple ventricular arrhythmias has been established at 5&nbsp;microgram per Kg.</p><p>&nbsp;</p><p><u>Inducers of CYP2E1</u></p><p>Medicinal products and compounds that increase the activity of cytochrome P450 isoenzyme CYP2E1, such as isoniazid and alcohol, may increase the metabolism of sevoflurane and lead to significant increases in plasma fluoride concentrations. Concomitant use of sevoflurane and isoniazid can potentiate the hepatotoxic effects of isoniazid.</p><p>&nbsp;</p><p><u>Indirect-acting sympathomimetics</u></p><p>There is a risk of acute hypertensive episode with the concomitant use of sevoflurane and indirect sympathomimetic medicinal products (amphetamines, ephedrine).</p><p>&nbsp;</p><p><u>Verapamil</u></p><p>Atrioventricular impairment of conduction was observed when verapamil and sevoflurane were administered at the same time.</p><p>&nbsp;</p><p><u>St John&rsquo;s Wort</u></p><p>Severe hypotension and delayed emergence from anaesthesia with halogenated inhalational anesthetics have been reported in patients treated long-term with St John&rsquo;s Wort.</p><p>&nbsp;</p><p><u>Barbiturates</u></p><p>Sevoflurane administration is compatible with barbiturates, propofol and other&nbsp; commonly used intravenous anaesthetics. Lower concentrations of sevoflurane may be required following use of an intravenous anaesthetic.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy </u></p><p>There are no or limited data from the use of sevoflurane in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3); therefore, sevoflurane should be used during pregnancy and in woman of childbearing potential not using contraception only if clearly needed.</p><p>&nbsp;</p><p><u>Labor and delivery</u></p><p>In a clinical trial, the safety of sevoflurane was demonstrated for mothers and infants when used for anesthesia during Cesarean section. The safety of sevoflurane in labor and vaginal delivery has not been demonstrated.</p><p>&nbsp;</p><p>Caution should be exercised in obstetric anesthesia due to the relaxant effect of sevoflurane on the uterus and increase in uterine hemorrhage.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>It is not known whether sevoflurane is excreted in human milk. Caution should be exercised when sevoflurane is administered to a nursing woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Studies in animals have shown adverse effects on fertility (see section 5.3). There are no data on effects on fertility in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be advised that performance of activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, may be impaired for some time after general anesthesia (see section 4.4).Patients should not drive following sevoflurane anaesthesia for a period determined by the anaesthetist.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>As with all potent inhalational anaesthetics, sevoflurane can produce dose-dependent cardiac respiratory depression. Most of the adverse reactions are mild to moderate in severity and transient in duration. Nausea and vomiting have been reported in the post-operative period &ndash; common symptoms following surgery and general anaesthesia &ndash; which may be due to the inhalational anaesthetic, other agents administered intra-operatively or post-operatively, or the patient&rsquo;s reaction to the surgical procedure.</p><p>&nbsp;</p><p>The most commonly reported adverse reactions were as follows:</p><p>In adult patients: hypotension, nausea and vomiting;</p><p>In elderly patients: bradycardia, hypotension and nausea; and</p><p>In paediatric patients: agitation, cough, vomiting and nausea.</p><p>&nbsp;</p><p><u>Tabulated summary of adverse reactions</u></p><p>All reactions, at least possibly related to sevoflurane from clinical trials and post-marketing experience, are displayed in the Table below by MedDRA System Organ Class, Preferred Term and frequency. The following frequency groupings are used: very common (&ge;1/10); common (&ge;1/100 and &lt;1/10); uncommon (&ge;1/1,000 and &lt;1/100); rare (&ge;1/10,000 and &lt;1/1,000); very rare (&lt;1/10,000), including isolated reports. Post-marketing adverse reactions are reported voluntarily from a population with an unknown rate of exposure. Therefore it is not possible to estimate the true incidence of adverse events and the frequency is &ldquo;unknown&rdquo;. The type, severity, and frequency of adverse reactions in sevoflurane patients in clinical trials were comparable to adverse reactions in reference-drug patients.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Adverse Reaction Data Derived From Clinical Trials and Post-marketing Experience</u></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Summary of Most Frequent Adverse Drug Reactions in Sevoflurane Clinical Trials and Post-marketing Experience</p></td></tr><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Frequency</p></td><td style="vertical-align:top"><p>Adverse Reactions</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>Anaphylactic reaction <sup>1</sup></p><p>Anaphylactoid reaction</p><p>Hypersensitivity <sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Very Common</p><p>Uncommon</p><p>Unknown</p></td><td style="vertical-align:top"><p>Agitation</p><p>Confusion</p><p>Delirium</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Unknown</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Somnolence</p><p>Dizziness</p><p>Headache</p><p>&nbsp;</p><p>Convulsion <sup>2 3</sup></p><p>Dystonia</p><p>Increased intracranial pressure</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very Common</p><p>Common</p><p>Uncommon</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Unknown</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bradycardia</p><p>Tachycardia</p><p>Atrioventricular block complete, Cardiac arrhythmias (including ventricular arrhythmias), atrial fibrillation, extrasystoles (ventricular, supra-ventricular, bigeminy-linked),</p><p>Cardiac arrest<sup> 4</sup></p><p>Ventricular fibrillation</p><p>Torsades de pointes</p><p>Ventricular tachycardia, Electrocardiogram QT prolonged</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Very Common</p><p>Common</p></td><td style="vertical-align:top"><p>Hypotension</p><p>Hypertension</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Very Common</p><p>Common</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Uncommon</p><p>&nbsp;</p><p>&nbsp;</p><p>Unknown</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cough</p><p>Respiratory disorder</p><p>Respiratory depression</p><p>Laryngospasm</p><p>Airway obstruction</p><p>Apnoea</p><p>Asthma</p><p>Hypoxia</p><p>Bronchospasm</p><p>Dyspnoea <sup>1</sup></p><p>Wheezing <sup>1</sup></p><p>Breath holding</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very Common</p><p>&nbsp;</p><p>Common</p><p>Unknown</p></td><td style="vertical-align:top"><p>Nausea</p><p>Vomiting</p><p>Salivary hypersecretion</p><p>Pancreatitis</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism And Nutrition Disorders</p></td><td style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>Hyperkalemia</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal connective tissue and bone disorders</p></td><td style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>Muscle rigidity</p></td></tr><tr><td style="vertical-align:top"><p>Hepato-biliary disorders</p></td><td style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>Hepatitis <sup>1 2</sup></p><p>Hepatic failure <sup>1 2</sup></p><p>Hepatic necrosis <sup>1 2</sup></p><p>Jaundice</p></td></tr><tr><td style="vertical-align:top"><p>Renal and Urinary Disorders</p></td><td style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>Tubulointerstitial nephritis</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>Dermatitis contact <sup>1</sup></p><p>Pruritus</p><p>Rash <sup>1</sup></p><p>Swelling face <sup>1</sup></p><p>Urticaria</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>Unknown</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Chills</p><p>Pyrexia</p><p>Chest discomfort <sup>1</sup></p><p>Hyperthermia malignant <sup>1 2</sup></p><p>Edema</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Uncommon</p></td><td style="vertical-align:top"><p>Blood glucose abnormal</p><p>Liver function test abnormal <sup>5</sup></p><p>White blood cell count abnormal</p><p>Blood fluoride increased<sup>1</sup></p><p>Serum Creatinine increased</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypothermia</p></td></tr></tbody></table><p><sup>1</sup> See section 4.8 &ndash; Description of selected adverse reactions.</p><p><sup>2</sup> See section 4.4.</p><p><sup>3</sup> See section 4.8 &ndash; Paediatric population.</p><p><sup>4 </sup>There have been very rare postmarketing reports of cardiac arrest in the setting of sevoflurane use.</p><p><sup>5</sup> Occasional cases of transient changes in hepatic function tests<strong> </strong>were reported with sevoflurane and reference agents.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>Transient increases in serum inorganic fluoride levels<strong> </strong>may occur during and after sevoflurane anaesthesia. Concentrations of inorganic fluoride generally peak within two hours of the end of sevoflurane anaesthesia and return within 48 hours to pre-operative levels. In clinical trials, elevated fluoride concentrations were not associated with impairment of renal function.</p><p>&nbsp;</p><p>Rare reports of post-operative hepatitis exist.&nbsp; In addition, there have been rare post-marketing reports of hepatic failure and hepatic necrosis associated with the use of potent volatile anaesthetic agents, including sevoflurane. However, the actual incidence and relationship of sevoflurane to these events cannot be established with certainty (see section 4.4).</p><p>&nbsp;</p><p>Rare reports of hypersensitivity(including contact dermatitis, rash, dyspnoea, wheezing, chest discomfort, swelling face, eyelid edema, erythema, urticaria, pruritis bronchospasm, anaphylactic or anaphylactoid reactions have been reported particularly in association with long-term occupational exposure to inhaled anaesthetic agents, including sevoflurane.</p><p>&nbsp;</p><p>In susceptible individuals, potent inhalation anaesthetic agents may trigger a skeletal muscle hypermetabolic state leading to high oxygen demand and the clinical syndrome known as malignant hyperthermia (see section 4.4).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The use of sevoflurane has been associated with seizures. Many of these have occurred in children and young adults starting from 2 months of age, most of whom had no predisposing risk factors. Several cases reported no concomitant medications, and at least one case was confirmed by electroencephalography (EEG). Although many cases were single seizures that resolved spontaneously or after treatment, cases of multiple seizures have also been reported. Seizures have occurred during, or soon after Sevoflurane induction, during emergence, and during post-operative recovery up to a day following anaesthesia. Clinical judgment should be exercised when using sevoflurane in patients who may be at risk for seizures (see section 4.4).</p><p>&nbsp;</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continue monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed below.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>&nbsp;</p><ul><li><strong>Saudi Arabia:</strong></li></ul><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms of overdose include respiratory depression and circulatory insufficiency.</p><p>&nbsp;</p><p>In the event of apparent overdosage the following action should be taken: Sevoflurane administration should be discontinued and supportive measures provided: the patient&rsquo;s airway should be maintained and artificial or controlled ventilation with pure oxygen should be instituted, along with measures to maintain stable cardiovascular function.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: anaesthetics, general; halogenated hydrocarbons.</p><p>ATC code: N 01 AB 08</p><p>&nbsp;</p><p>Sevoflurane is a halogenated methyl isopropyl ether inhalational anaesthetic which produces a rapid induction and recovery phase. MAC (minimum alveolar concentration) is age specific (see Section&nbsp;4.2).</p><p>&nbsp;</p><p>Sevoflurane produces loss of consciousness, reversible abolition of pain and motor activity, diminution of autonomic reflexes, respiratory and cardiovascular depression. These effects are dose-dependent.</p><p>&nbsp;</p><p>Sevoflurane has a low blood/gas partition coefficient (0.65) leading to a rapid recovery from anaesthesia.</p><p>&nbsp;</p><p>Cardiovascular effects:&nbsp; Sevoflurane may produce concentration-related decrease of blood pressure. Sevoflurane produces a sensitisation of the myocardium to the arrhythmogenic effect of exogenously administered epinephrine.&nbsp; This sensitisation is similar to that produced by isoflurane.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sevoflurane is weakly soluble in blood and tissue, resulting in the rapid achievement of a sufficient alveolar concentration to produce anaesthesia and a subsequent rapid elimination until cessation of anaesthesia.</p><p>&nbsp;</p><p>In humans, &lt; 5% of sevoflurane absorbed is metabolised in the liver to hexafluoroisopropanol (HFIP) with release of inorganic fluoride and carbon dioxide (or a one carbon fragment).&nbsp; Once formed, HFIP is rapidly conjugated with glucuronic acid and eliminated in the urine.</p><p>&nbsp;</p><p>The rapid and extensive pulmonary elimination of sevoflurane minimises the quantity available for metabolism. The metabolism of sevoflurane is not induced by barbiturates.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data on single and repeated dose toxicity of sevoflurane showed no specific organ toxicity.</p><p>&nbsp;</p><p>Reproductive studies:&nbsp; Studies on fertility performed in rats indicated a decrease in implantation and pregnancy rates after repeated exposure to anaesthetic doses.&nbsp; Developmental toxicity studies performed in rats and rabbits did not reveal any teratogenic effect.&nbsp; In sub-anaesthetic concentrations during the perinatal phase rats showed a prolongation of gestation.</p><p>&nbsp;</p><p>A study in male rats has demonstrated decreased sperm motility and concentration as well as increased testicular degeneration after chronic exposure to sevoflurane (1 MAC sevoflurane inhalation for 7 or 14 days) compared to controls.</p><p>&nbsp;</p><p>Published studies in animals (including primates) at doses resulting in light to moderate anaesthesia demonstrate that the use of anaesthetic agents during the period of rapid brain growth or synaptogenesis results in cell loss in the developing brain that can be associated with prolonged cognitive deficiencies. The clinical significance of these nonclinical findings in not known.</p><p>&nbsp;</p><p>Extensive in-vitro and in-vivo mutagenicity studies with sevoflurane yielded negative results.&nbsp; Carcinogenicity studies were not performed.</p><p>&nbsp;</p><p>Effects on circulatory function and oxygen consumption:&nbsp; The results of studies conducted in dogs indicate that sevoflurane does not cause any coronary steal syndrome and does not exacerbate a pre-existing myocardial ischaemia.&nbsp; Animal studies have shown that liver and kidney circulation is maintained well with sevoflurane.</p><p>&nbsp;</p><p>Sevoflurane decreases the cerebral metabolic rate for oxygen (CMRO<sub>2</sub>) in a fashion analogous to that seen with isoflurane.&nbsp;</p><p>&nbsp;</p><p>An approximately 50% reduction of CMRO<sub>2 </sub>is observed at concentrations approaching 2.0&nbsp;MAC.&nbsp; Animal studies have demonstrated that sevoflurane does not have a significant effect on cerebral blood flow.</p><p>&nbsp;</p><p>Effects of sevoflurane on the central nervous system:&nbsp; In animals, sevoflurane significantly suppresses electroencephalographic (EEG) activity comparable to equipotent doses of isoflurane.&nbsp; There is no evidence that sevoflurane is associated with epileptiform activity during normocapnia or hypocapnia.&nbsp; In contrast to enflurane, attempts to elicit seizure-like EEG activity during hypocapnia with rhythmic auditory stimuli have been negative.</p><p>&nbsp;</p><p>Compound&nbsp;A:&nbsp; Compound&nbsp;A is a degradation product of sevoflurane, which is generated in CO<sub>2</sub>-absorbers.&nbsp; Its concentration increases normally with increasing absorber temperature, sevoflurane concentration and lowering of the fresh gas flow rate.</p><p>&nbsp;</p><p>Studies performed in rats have shown a dose and duration of exposure dependent, reversible, nephrotoxicity (single cell necrosis of the proximal tubule cells).&nbsp; In the rat evidence for nephrotoxicity could be found at 25-50&nbsp;ppm following 6 and 12&nbsp;hours exposure.&nbsp; The relevance to humans is unknown.</p><p>&nbsp;</p><p>In clinical studies the highest concentration of Compound&nbsp;A (using soda lime as CO<sub>2</sub> absorbents in the circuit) was 15&nbsp;ppm in children and 32&nbsp;ppm in adults.&nbsp; In systems using barium lime as CO<sub>2</sub> absorbents concentrations of up to 61&nbsp;ppm were found.&nbsp; Although the experience with low-flow anaesthesia is limited, to date there is no evidence of kidney impairment due to Compound&nbsp;A.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the clinical setting, through direct contact with CO<sub>2</sub> absorbents (Soda lime and barium hydroxide lime), sevoflurane can degrade producing low levels of Compound&nbsp;A (pentafluoroisopropenyl fluoromethyl ether (PIFE)), and trace amounts of Compound&nbsp;B (pentfluoromethoxy isopropyl fluoromethyl ether (PMFE)).&nbsp; The interaction with CO<sub>2</sub> absorbents is not unique to sevoflurane.&nbsp; The production of degradants in the anaesthesia circuit results from the extraction of the acidic proton in the presence of a strong base (potassium hydroxide (KOH) and/or sodium hydroxide (NaOH)) forming an alkene (Compound&nbsp;A) from sevoflurane.&nbsp; No dose adjustment or change in clinical practice is necessary when rebreathing circuits are used.</p><p>&nbsp;</p><p>Higher levels of Compound&nbsp;A are obtained when using barium hydroxide lime rather than soda lime.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Bottles with a plastic screw-on cap: 48 months
- Bottles with an integrated valve: 36 months

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&ordm;C</p><p>Do not refrigerate or freeze.</p><p>Store in upright position with cap firmly in place.</p><p>Keep this medicine out of sight and reach of children.</p><p>Do not use Sevoflurane Baxter after the expiry date that is printed on the label. The expiry date refers to the last day of that month.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>250&nbsp;ml aluminium bottles, lined with an internal epoxyphenolic resin protective lacquer. The bottles are closed with:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; plastic screw-on caps with a polytetrafluoroethylene (PTFE) laminate inner liner;</p><p>&nbsp;or</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an integrated crimped-on valve closure with stainless steel, nylon, ethylene-propylene copolymer (EPDM) and polyethylene product contact components.</p><p>&nbsp;</p><p>Pack sizes of 1 and 6&nbsp;bottles.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sevoflurane should be administered with a vaporiser calibrated specifically for sevoflurane. Filling occurs directly from the bottle via an integrated valve or, in case of a bottle without integrated valve, with the use of an appropriate adaptor designed specifically to fit the sevoflurane vaporiser.&nbsp; Only vaporisers demonstrated to be compatible with this medicinal product should be used for administration.&nbsp; Sevoflurane has been found to undergo degradation in the presence of strong Lewis acids that may be formed on metal or glass surfaces under harsh conditions, and the use of vaporisers that contain such strong Lewis acids, or that may form them under conditions of normal use, must be avoided.</p><p>&nbsp;</p><p>Carbon dioxide absorbents should not be allowed to dry out when inhalational anaesthetics are being administered.&nbsp; If the CO<sub>2</sub> absorbent is suspected to be desiccated it should be replaced.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Baxter Healthcare Corporation
Deerfield
60015
IL, USA

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                31 March 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>